Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cadila Shifts US Injectables Production From Plant After Tough FDA Inspection

Executive Summary

Expert investigators found many problems at Ahmedabad plant, warning letter and Form 483 report show.

You may also be interested in...



Zydus Cadila’s New Injectables Plant Could Help Blunt US Drug Shortages

Site switch also could trigger ANDA approvals sidelined as Moraiya plant recovers from US FDA warning letter.

The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities

Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.

US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

Topics

Related Companies

UsernamePublicRestriction

Register

PS141205

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel